Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,255 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review.
Patel S, Gandhi A, Pabani A, Shah R, Shah P, Martinez MW, Bavishi A. · J Am Heart Assoc · 2026 · cited 0 timessystematic review
- A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy.
Bal HS, Pampana A, Nayak A, Gaonkar M, Patel S, Yerabolu K, Vekariya N, Patel N, Kalra R, Li P, Arora G, Arora P. · Nat Cardiovasc Res · 2026 · cited 0 timesmeta-analysis
- Impact of diabetes on outcomes in hypertrophic cardiomyopathy: a GRADE meta-analysis.
Mirzohreh ST, Deravi N, Javanshir E, Asghari Jafarabadi M, Roshanravan N. · Heart · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Initial Clinical Experience.
Fang J, Chen Y, Zhou W, Li R, Gong C, Du J, Wang H, Wang Q, Cheng L, Wang C, Chen T, Ma Y, Zhu Y, Zhou J, Zhu X, Schaff HV, Liu Y, Wan S, Wei X. · Circulation · 2026 · cited 0 timesOpen accessclinical trial
- Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
Maron MS, Masri A, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, Arad M, Choudhury L, Claggett BL, Coats CJ, de Barros Correia E, Costabel JP, Elliott PM, Silva Enciso JE, Ge J, Ho CY, Kulac I, Lewis GD, Martinez MW, Maurer MS, Michels M, Mitter SS, Pino Moreno JE, Olivotto I, Owens AT, Poulsen SH, Rader F, Rowin EJ, Schulze PC, Sepp R, Sikand N, Solomon SD, Spertus JA, Zhao X, Divanji PH, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Salazar-Mendiguchía J, Wohltman A, Zhuo S, Barriales-Villa R, ACACIA-HCM Investigators. · Circulation · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Effect of Aficamten on Cardiac Structure and Function in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Hegde SM, Wang X, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, Arad M, Barriales-Villa R, Choudhury L, Claggett BL, Coats CJ, de Barros Correia E, Costabel JP, Elliott PM, Silva Enciso JE, Garcia-Pavia P, Ge J, Ho CY, Lakdawala NK, Lewis GD, Maron MS, Martinez MW, Masri A, Maurer MS, Michels M, Mitter SS, Pino Moreno JE, Nagy V, Olivotto I, Owens AT, Poulsen SH, Rader F, Rowin EJ, Ruda M, Schulze PC, Sikand N, Spertus JA, Zhao X, Divanji PH, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Salazar-Mendiguchía J, Wohltman A, Zhuo S, Solomon SD, ACACIA-HCM Investigators. · Circulation · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.
Rossano JW, Canter C, Wolf CM, Papez A, Gambra M, Bryant RM, Alejos J, McCulloch M, Sarquella Brugada G, Bock MJ, Jeewa A, Pearce FB, Desai MY, Favatella N, Javidialsaadi A, Phung V, Rano T, Zhu L, Dyme JL, Mital S, SCOUT-HCM Investigators. · N Engl J Med · 2026 · cited 7 timesclinical trial, phase iii, multicenter study
- Body Mass Index, Valsartan, and Myocardial Remodeling in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial.
Ostrominski JW, Claggett BL, Jerosch-Herold M, Raja AA, Day SM, Russell MW, Zahka K, Pereira AC, Colan SD, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Soslow JH, Becker JR, Lakdawala NK, Bundgaard H, Vargas JD, Ho CY, Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators. · J Am Heart Assoc · 2026 · cited 0 timesOpen accessclinical trial, phase ii, multicenter study
- Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials.
Olivotto I, Garcia-Pavia P, Tian Z, Owens AT, Lakdawala NK, Balaratnam G, Zhong Y, Memaj A, Barrett YC, Desai M. · Am Heart J · 2027 · cited 1 timesmeta-analysis
- Metabolomic biomarkers and metabolic remodelling in genetically characterised hypertrophic cardiomyopathy: a systematic review.
Ahmad Razmy AH, Abd Latip N, Ab-Rahim S, Sheikh Abdul Kadir SH. · Metabolomics · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- Exercise Training and Cardiac Remodeling in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.
Weber M, Azouz M, Young E, Appajodu M, Bettag J, Milkie D, Kabach A. · Crit Pathw Cardiol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM.
Weiner SD, Liang LW, Masri A, Abraham TP, Barriales-Villa R, Cooper RM, Elliott PM, de Feria A, Maron MS, Oreziak A, Saberi S, Solomon SD, Spertus JA, Tower-Rader A, Butzner M, Godown J, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Nassif ME, Owens AT, FOREST-HCM Investigators. · Eur J Heart Fail · 2026 · cited 1 timesclinical trial, phase iii, clinical trial, phase ii
- Prevalence and clinical characteristics of sleep apnea in hypertrophic cardiomyopathy: A meta-analysis.
Du D, Liu S, He S, An N, Shen Y, Luo F. · Sleep Breath · 2026 · cited 0 timesmeta-analysis, review
- Circulating MicroRNAs and Clinical Parameters in Hypertrophic Cardiomyopathy: A Systematic Review and Correlation Meta-Analysis.
Menezes Junior ADS, de Oliveira HL, de Lima KBA. · Front Biosci (Schol Ed) · 2026 · cited 0 timesmeta-analysis, systematic review
- Comparative efficacy of pharmacological therapies in non-obstructive hypertrophic cardiomyopathy: a frequentist network meta-analysis.
Kumar G B, S M, Ibrahimpur NS, M R, Meher BR. · Eur J Clin Pharmacol · 2026 · cited 0 timescomparative study, review
- Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM, MAPLE-HCM Investigators. · JAMA Cardiol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Efficacy and safety of exercise for hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Amin AM, Shehada W, Elgebaly M, Ayman D, Ibrahim MM, Abdelazeem B, Felpel K. · Proc (Bayl Univ Med Cent) · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Fibro-Inflammatory Signaling, Fibrosis, and Microvascular Ischemia as Convergent Translational Substrates of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: A Systematic Review.
da Silva Menezes Junior A, Wastowski IJ, Carneiro LC. · J Cardiovasc Transl Res · 2026 · cited 0 timessystematic review
- Cardiovascular biomarkers in feline hypertrophic cardiomyopathy phenotype: evidence from the last decade.
de Sousa FG, Muzzi RAL, Magalhães FDC, de Araújo RB, Faleiros RR, Beier SL. · Vet Res Commun · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Exercise Training in Hypertrophic Cardiomyopathy: A Systematic Review, Meta-analysis, and Meta-regression.
Bayonas-Ruiz A, Gimeno-Blanes JR, Muñoz-Franco FM, Sabater-Molina M, Bonacasa B. · Sports Med Open · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Sex-disaggregated data in hypertrophic cardiomyopathy: a targeted literature review, meta-analysis and primary cohort study.
Lim VG, Kokara M, Jarrett A, Panicker A, Kimani P, Sadlowski C, Osman F. · Open Heart · 2026 · cited 0 timesOpen accessmeta-analysis, review
- Circulating microRNA dysregulation in hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, and dilated cardiomyopathy: a systematic review.
Léger L, Ferron S, Pauwels NS, Lingier F, Rodriguez-Muñoz A, Murri-Pierri M, van Hengel J, Calore M. · Syst Rev · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials.
Fahim M, Eldawud D, Wahadneh O, Wang R, Gorantla A, Sharma N, Khouri P, Salciccioli L. · Am J Cardiol · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients.
Veselka J, Gimeno R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Masri A, Miao ZM, Nassif ME, Olivotto I, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Maron MS, SEQUOIA-HCM Investigators. · Am J Cardiol · 2026 · cited 0 timesmulticenter study, randomized controlled trial
- Rationale and design of the TAILOR-HCM multicenter randomized controlled trial: Transapical beating-heart septal myectomy for obstructive hypertrophic cardiomyopathy.
Fang J, Ma Y, Chen Y, Lai Y, Wang C, Guo H, Ma L, Yan X, Wang D, Wan S, Wei X. · Am Heart J · 2026 · cited 0 timesclinical trial protocol
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.